A recent study conducted in Denmark has concluded that the combination of the cancer drugs Navelbine (vinorelbine) and Platinol (cisplatin) are “highly active” when treating patients with “newly diagnosed non-resectable malignant pleural mesothelioma.” Study details were included in a publication released by the British Journal on June 10th.
Common side affects associated with Navelbine, an anti-cancer chemotherapy drug, include low blood counts, muscle weakness, and vomiting. The side effects of Platinol are very similar, although many patients do not experience unpleasant effects at all. Both drugs are administered intravenously.
Pleural mesothelioma is a fatal type of cancer that affects the pleural lining of the lungs and is caused by exposure to high levels of asbestos, a known carcinogen. Patients diagnosed with mesothelioma generally succumb to this aggressive disease in less than two years. Presently, there is no known cure for mesothelioma, and the survival rate is less than one percent.
A total of 54 patients participated in the study, with all receiving four rounds of Navelbine and Platinol treatment. The median survival rate associated with the study was 16.8 months, with three-year survival rates around 4%.
The Mesothelioma & Asbestos Awareness Center recognize this breakthrough mesothelioma treatment method and support ongoing research related to Navelbine and Platinol treatments.
The Mesothelioma & Asbestos Awareness Center is the web’s foremost resource for information related to pleural mesothelioma, mesothelioma treatment methods, top physicians, and more. For further information, please visit the Mesothelioma & Asbestos Awareness Center.
